Mad Money Recap
Cramer's 'Mad Money' Recap: Next Week's Game Plan (Final)
Intriguing Cancer Play
Cramer spoke with Dr. George Scangos, president and CEO of Exelixis (EXEL), the last in a series this week of biotech companies battling cancer. Exelixis' primary drug, XL184, is currently in phase II testing for thyroid cancer. Scangos said that drug discovery and development is a long-term process, taking 10 years or more to complete, so he's not worried that his company has yet to turn a profit. He said that biotech companies should be measured by the compounds they've developed and by the data those compounds are generating. When asked about the company's financial position, Scangos said that Exelixis has been very successful in raising cash without the capital markets. The company's large pharma partners have also been instrumental is assuming large portions of the developments costs, he said. Cramer said while Exelixis is intriguing, he prefers to wait for the company's next update on their drugs' performance on Nov. 15 before committing any cash to the company.Lightning Round
Cramer was bullish on Caterpillar (CAT), Hain Celestial Group (HAIN), Starbucks (SBUX), Intel (INTC) and NVIDIA (NVDA). He was bearish on Fairchild Semiconductor (FCS). > > Bull or Bear? Vote in Our Poll To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.|
|
TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,393.45 | 1,310.33 | 2,827.34 | 15.81 |
Oil *
101.78
|
|
DOWN
26.41 |
DOWN
2.99 |
DOWN
10.02 |
DOWN
0.44 |
10 Yr
1.58%
SPDR Gold
151.62
|
|
-0.21%
|
-0.23%
|
-0.35%
|
-2.71%
|
Data delayed 20 minutes |


Connect with TheStreet